ProNAi Therapeutics, Inc. (NASDAQ:SRRA) – Jefferies Group issued their FY2021 earnings per share (EPS) estimates for shares of ProNAi Therapeutics in a research note issued to investors on Monday. Jefferies Group analyst M. Raycroft forecasts that the biotechnology company will post earnings per share of ($0.95) for the year. Jefferies Group currently has a “Buy” rating on the stock.

Other analysts have also issued research reports about the stock. ValuEngine raised shares of ProNAi Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research raised shares of ProNAi Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $4.00.

TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at

ProNAi Therapeutics (NASDAQ:SRRA) traded up 5.7200% on Tuesday, reaching $1.8501. 643,687 shares of the company’s stock traded hands. ProNAi Therapeutics has a 52-week low of $1.10 and a 52-week high of $1.94. The stock’s market cap is $96.70 million. The company’s 50 day moving average is $1.65 and its 200-day moving average is $1.41.

ProNAi Therapeutics (NASDAQ:SRRA) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.01.

An institutional investor recently bought a new position in ProNAi Therapeutics stock. FMR LLC acquired a new position in ProNAi Therapeutics, Inc. (NASDAQ:SRRA) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 197,100 shares of the biotechnology company’s stock, valued at approximately $302,000. FMR LLC owned 0.38% of ProNAi Therapeutics as of its most recent filing with the Securities & Exchange Commission. 55.72% of the stock is currently owned by institutional investors and hedge funds.

ProNAi Therapeutics Company Profile

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Receive News & Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related companies with's FREE daily email newsletter.